LD50=580 mg/kg in rats
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Pegvisomant | The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Disopyramide. |
| Deferasirox | The serum concentration of Disopyramide can be increased when it is combined with Deferasirox. |
| Peginterferon alfa-2b | The serum concentration of Disopyramide can be increased when it is combined with Peginterferon alfa-2b. |
| Leflunomide | The serum concentration of Disopyramide can be decreased when it is combined with Leflunomide. |
| Teriflunomide | The serum concentration of Disopyramide can be decreased when it is combined with Teriflunomide. |
| Esmolol | Disopyramide may increase the bradycardic activities of Esmolol. |
| Betaxolol | Disopyramide may increase the bradycardic activities of Betaxolol. |
| Metoprolol | Disopyramide may increase the bradycardic activities of Metoprolol. |
| Atenolol | Disopyramide may increase the bradycardic activities of Atenolol. |
| Timolol | Disopyramide may increase the bradycardic activities of Timolol. |
| Propranolol | Disopyramide may increase the bradycardic activities of Propranolol. |
| Labetalol | Disopyramide may increase the bradycardic activities of Labetalol. |
| Alprenolol | Disopyramide may increase the bradycardic activities of Alprenolol. |
| Pindolol | Disopyramide may increase the bradycardic activities of Pindolol. |
| Carvedilol | Disopyramide may increase the bradycardic activities of Carvedilol. |
| Acebutolol | Disopyramide may increase the bradycardic activities of Acebutolol. |
| Nadolol | Disopyramide may increase the bradycardic activities of Nadolol. |
| Bevantolol | Disopyramide may increase the bradycardic activities of Bevantolol. |
| Practolol | Disopyramide may increase the bradycardic activities of Practolol. |
| Penbutolol | Disopyramide may increase the bradycardic activities of Penbutolol. |
| Oxprenolol | Disopyramide may increase the bradycardic activities of Oxprenolol. |
| Dexpropranolol | Disopyramide may increase the bradycardic activities of Dexpropranolol. |
| Celiprolol | Disopyramide may increase the bradycardic activities of Celiprolol. |
| Nebivolol | Disopyramide may increase the bradycardic activities of Nebivolol. |
| Bufuralol | Disopyramide may increase the bradycardic activities of Bufuralol. |
| Bopindolol | Disopyramide may increase the bradycardic activities of Bopindolol. |
| Bupranolol | Disopyramide may increase the bradycardic activities of Bupranolol. |
| Indenolol | Disopyramide may increase the bradycardic activities of Indenolol. |
| Arotinolol | Disopyramide may increase the bradycardic activities of Arotinolol. |
| Levobetaxolol | Disopyramide may increase the bradycardic activities of Levobetaxolol. |
| Talinolol | Disopyramide may increase the bradycardic activities of Talinolol. |
| Anisodamine | Disopyramide may increase the bradycardic activities of Anisodamine. |
| Bucindolol | Disopyramide may increase the bradycardic activities of Bucindolol. |
| Esatenolol | Disopyramide may increase the bradycardic activities of Esatenolol. |
| Cloranolol | Disopyramide may increase the bradycardic activities of Cloranolol. |
| Mepindolol | Disopyramide may increase the bradycardic activities of Mepindolol. |
| Epanolol | Disopyramide may increase the bradycardic activities of Epanolol. |
| Tertatolol | Disopyramide may increase the bradycardic activities of Tertatolol. |
| Landiolol | Disopyramide may increase the bradycardic activities of Landiolol. |
| Erythromycin | Erythromycin may increase the QTc-prolonging activities of Disopyramide. |
| Sirolimus | Sirolimus may increase the QTc-prolonging activities of Disopyramide. |
| Dirithromycin | Dirithromycin may increase the QTc-prolonging activities of Disopyramide. |
| Telithromycin | Telithromycin may increase the QTc-prolonging activities of Disopyramide. |
| Candicidin | Candicidin may increase the QTc-prolonging activities of Disopyramide. |
| Clarithromycin | Clarithromycin may increase the QTc-prolonging activities of Disopyramide. |
| Josamycin | Josamycin may increase the QTc-prolonging activities of Disopyramide. |
| Everolimus | Everolimus may increase the QTc-prolonging activities of Disopyramide. |
| Epothilone D | Epothilone D may increase the QTc-prolonging activities of Disopyramide. |
| Patupilone | Patupilone may increase the QTc-prolonging activities of Disopyramide. |
| 6-Deoxyerythronolide B | 6-Deoxyerythronolide B may increase the QTc-prolonging activities of Disopyramide. |
| Ixabepilone | Ixabepilone may increase the QTc-prolonging activities of Disopyramide. |
| KOS-1584 | KOS-1584 may increase the QTc-prolonging activities of Disopyramide. |
| Ridaforolimus | Ridaforolimus may increase the QTc-prolonging activities of Disopyramide. |
| Temsirolimus | Temsirolimus may increase the QTc-prolonging activities of Disopyramide. |
| AVE9633 | AVE9633 may increase the QTc-prolonging activities of Disopyramide. |
| Coltuximab ravtansine | Coltuximab ravtansine may increase the QTc-prolonging activities of Disopyramide. |
| Cethromycin | Cethromycin may increase the QTc-prolonging activities of Disopyramide. |
| Mitemcinal | Mitemcinal may increase the QTc-prolonging activities of Disopyramide. |
| Brefeldin A | Brefeldin A may increase the QTc-prolonging activities of Disopyramide. |
| Solithromycin | Solithromycin may increase the QTc-prolonging activities of Disopyramide. |
| Kitasamycin | Kitasamycin may increase the QTc-prolonging activities of Disopyramide. |
| Carbomycin | Carbomycin may increase the QTc-prolonging activities of Disopyramide. |
| Doramectin | Doramectin may increase the QTc-prolonging activities of Disopyramide. |
| Eprinomectin | Eprinomectin may increase the QTc-prolonging activities of Disopyramide. |
| Oleandomycin | Oleandomycin may increase the QTc-prolonging activities of Disopyramide. |
| Selamectin | Selamectin may increase the QTc-prolonging activities of Disopyramide. |
| Tildipirosin | Tildipirosin may increase the QTc-prolonging activities of Disopyramide. |
| Tilmicosin | Tilmicosin may increase the QTc-prolonging activities of Disopyramide. |
| Tylosin | Tylosin may increase the QTc-prolonging activities of Disopyramide. |
| Tylvalosin | Tylvalosin may increase the QTc-prolonging activities of Disopyramide. |
| Bryostatin 1 | Bryostatin 1 may increase the QTc-prolonging activities of Disopyramide. |
| Lorvotuzumab mertansine | Lorvotuzumab mertansine may increase the QTc-prolonging activities of Disopyramide. |
| Epofolate | Epofolate may increase the QTc-prolonging activities of Disopyramide. |
| Sagopilone | Sagopilone may increase the QTc-prolonging activities of Disopyramide. |
| Troleandomycin | Troleandomycin may increase the QTc-prolonging activities of Disopyramide. |
| Miocamycin | Miocamycin may increase the QTc-prolonging activities of Disopyramide. |
| Flurithromycin | Flurithromycin may increase the QTc-prolonging activities of Disopyramide. |
| Rokitamycin | Rokitamycin may increase the QTc-prolonging activities of Disopyramide. |
| Midecamycin | Midecamycin may increase the QTc-prolonging activities of Disopyramide. |
| Clindamycin | Clindamycin may increase the QTc-prolonging activities of Disopyramide. |
| Mepartricin | Mepartricin may increase the QTc-prolonging activities of Disopyramide. |
| Aclidinium | The risk or severity of adverse effects can be increased when Disopyramide is combined with Aclidinium. |
| Mianserin | Mianserin may increase the anticholinergic activities of Disopyramide. |
| Mirabegron | The risk or severity of urinary retention can be increased when Disopyramide is combined with Mirabegron. |
| Potassium chloride | The risk or severity of gastrointestinal ulceration can be increased when Disopyramide is combined with Potassium chloride. |
| Pramlintide | The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Disopyramide. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Disopyramide. |
| Tiotropium | The risk or severity of adverse effects can be increased when Disopyramide is combined with Tiotropium. |
| Topiramate | The risk or severity of hyperthermia and oligohydrosis can be increased when Disopyramide is combined with Topiramate. |
| Umeclidinium | The risk or severity of adverse effects can be increased when Disopyramide is combined with Umeclidinium. |
| Fosphenytoin | The serum concentration of Disopyramide can be decreased when it is combined with Fosphenytoin. |
| Amiodarone | Amiodarone may increase the QTc-prolonging activities of Disopyramide. |
| Fingolimod | Fingolimod may increase the arrhythmogenic activities of Disopyramide. |
| Phenytoin | The serum concentration of Disopyramide can be decreased when it is combined with Phenytoin. |
| Propafenone | Propafenone may increase the arrhythmogenic activities of Disopyramide. |
| Verapamil | The risk or severity of sinus node depression can be increased when Verapamil is combined with Disopyramide. |
| Glycopyrronium | The risk or severity of adverse effects can be increased when Disopyramide is combined with Glycopyrronium. |
| Lipoic acid | The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Disopyramide. |
| Abiraterone | The serum concentration of Disopyramide can be increased when it is combined with Abiraterone. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Disopyramide is combined with Botulinum toxin type A. |